FilingSEC EDGAR8-K
InMed Pharmaceuticals Reports Q1 Fiscal 2027 Results and Provides Merger Update
· SEC accepted
StageMerger in progress
Filing content
The company reported Q1 fiscal 2027 financial results, continues to pursue its merger with Mentari Therapeutics, and has until March 15, 2027, to regain compliance with Nasdaq's minimum shareholders' equity requirement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…